GLP-1 Receptor Agonists and Risk of Skin Cancer in Adults With Type 2 Diabetes: A Target Trial Emulation.
GLP-1 drugs used for diabetes show no meaningful increased melanoma risk, and any skin cancer concern largely disappears after accounting for study biases.
GLP-1 receptor agonist initiation was not associated with increased melanoma risk; a borderline NMSC risk increase vs SGLT2i (HR 1.06) was attenuated after negative-control outcome calibration, providing overall reassurance about GLP-1 RA cancer safety in type 2 diabetes patients. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- target trial emulation using electronic health records (n=235,797 matched pairs)
- Category
- cardiovascular_metabolic_glp1_sglt2
- Maturity
- Validated
- Journal
- Diabetes Obes Metab
Why it surfaced
Well-powered target trial emulation (235,797 pairs) providing cancer safety pharmacovigilance data for GLP-1 RAs — prescribed to tens of millions. Null/reassuring result for melanoma; borderline NMSC signal largely explained by confounding. Important for the cardiometabolic-oncology interface watchlist.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.